- Conditions
- Allergic Rhinitis
- Interventions
- 205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
- Drug · Other
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Vasomotor Rhinitis
- Interventions
- Olopatadine HCL (Patanase) Nasal Spray, 0.6%, Azelastine HCl (Astelin) Nasal Spray, 137 mcg
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas